5-甲氧基-3,4-二氢-1,8-萘啶-2(1H)-酮 | 1045855-18-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 5-甲氧基-3,4-二氢-1,8-萘啶-2(1H)-酮
• 英文名称: 5-Methoxy-3,4-dihydro-1,8-naphthyridin-2(1H)-one
• 英文别名: 5-methoxy-3,4-dihydro-1H-1,8-naphthyridin-2-one
• CAS: 1045855-18-2
• 化学式: C₉H₁₀N₂O₂
• mdl: MFCD11052857
• 分子量: 178.19
• InChiKey: NCIFEDWUPPJNEZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• WGK Germany：
  3

文献信息

• PIPERIDINE DERIVATIVE
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US20190040039A1

  公开（公告）日：2019-02-07

  The purpose of the present invention is to provide a compound having excellent antibacterial activity against mycobacterium tuberculosis , multidrug-resistant tuberculosis bacteria, and/or non-tuberculous acid-fast bacteria. A compound represented by formula [I]: (in the formula, each symbol is as described in the attached specification), or a salt thereof can be used to diagnose, prevent, and/or treat tuberculosis.

  本发明的目的是提供一种对结核分枝杆菌、多药耐药结核菌和/或非结核性抗酸杆菌具有优异抗菌活性的化合物。可以利用由化学式[I]表示的化合物（在该化学式中，每个符号如所附规范所述），或其盐来诊断、预防和/或治疗结核病。
• [EN] CHIRAL SYNTHESIS OF FUSED BICYCLIC RAF INHIBITORS<br/>[FR] SYNTHÈSE CHIRALE D'INHIBITEURS DE RAF BICYCLIQUES FUSIONNÉS
  申请人：JAZZ PHARMACEUTICALS IRELAND LTD

  公开号：WO2022023450A1

  公开（公告）日：2022-02-03

  The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitor enantiomers of formula (I), (Ia), (Ib), (II), (IIa), or (IIb), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, with high enantiomeric excess (%ee). The disclosure also relates to method of using the compound of formula (I), (Ia), (Ib), (II), (IIa), or (IIb), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for treating diseases such as cancer, including colorectal cancer.

  本公开涉及改进合成式(I)、(Ia)、(Ib)、(II)、(IIa)或(IIb)的融合双环Raf抑制剂对映体，或其药学上可接受的盐、互变异构体或立体异构体，其具有高对映体过量百分比(%ee)。本公开还涉及使用式(I)、(Ia)、(Ib)、(II)、(IIa)或(IIb)的化合物，或其药学上可接受的盐、互变异构体或立体异构体，治疗癌症等疾病，包括结直肠癌的方法。
• Piperidine derivative
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US10851079B2

  公开（公告）日：2020-12-01

  The purpose of the present invention is to provide a compound having excellent antibacterial activity against mycobacterium tuberculosis, multidrug-resistant tuberculosis bacteria, and/or non-tuberculous acid-fast bacteria. A compound represented by formula [I]: (in the formula, each symbol is as described in the attached specification), or a salt thereof can be used to diagnose, prevent, and/or treat tuberculosis.

  本发明的目的是提供一种对结核分枝杆菌、耐多药结核菌和/或非结核酸性无菌细菌具有优异抗菌活性的化合物。由式[I]代表的化合物： (式中，各符号如所附说明书所述）的化合物或其盐类可用于诊断、预防和/或治疗结核病。
• COMPOUNDS USEFUL FOR INHIBITING RAF DIMERS
  申请人：ALBERT EINSTEIN COLLEGE OF MEDICINE

  公开号：US20220265669A1

  公开（公告）日：2022-08-25

  The disclosure provides compounds of Formula I (Formula I) (c) And the pharmaceutically acceptable salts thereof. The A, B, C, and D rings and the variables R A , R B , R C , R D , L 0 , L 1 , L 2 , and L 2 , are defined herein. Compounds and salts of Formula I are useful as inhibitors of RAF kinase dimerization, including dimerization of wild type and mutant BRAF kinases. The disclosure includes pharmaceutical compositions comprising a compound or salt of Formula I. The disclosure also includes methods of treating a cancer susceptible to treatment with an inhibitor of BRAF dimers or BRAF dimerization, comprising administering a therapeutically effective amount of a compound or salt of Formula I to a patient in need of such treatment. These cancers susceptible to treatment with an inhibitor of BRAF dimers or BRAF dimerization include melanoma, thyroid cancer, hairy cell leukemia, ovarian cancer, lung cancer, and colorectal cancer.
• [EN] FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF<br/>[FR] INHIBITEURS DE RAF BICYCLIQUES FUSIONNÉS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：JAZZ PHARMACEUTICALS IRELAND LTD

  公开号：WO2022023447A2

  公开（公告）日：2022-02-03

  The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The disclosure also relates to method of using the compound of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for treating diseases such as cancer, including colorectal cancer.